| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | - | 54.345 | 36.790 | 56.682 | 80.514 |
| Total Income - EUR | - | - | - | - | - | - | 54.345 | 36.793 | 56.682 | 88.656 |
| Total Expenses - EUR | - | - | - | - | - | - | 39.481 | 34.499 | 55.237 | 71.717 |
| Gross Profit/Loss - EUR | - | - | - | - | - | - | 14.864 | 2.294 | 1.445 | 16.939 |
| Net Profit/Loss - EUR | - | - | - | - | - | - | 14.331 | 1.982 | 946 | 15.657 |
| Employees | - | - | - | - | - | - | 3 | 3 | 4 | 5 |
Check the financial reports for the company - Ubiphorma S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | - | 36 | 0 | 0 | 0 |
| Current Assets | - | - | - | - | - | - | 23.864 | 25.492 | 26.454 | 51.424 |
| Inventories | - | - | - | - | - | - | 0 | 2.943 | 1.377 | 1.370 |
| Receivables | - | - | - | - | - | - | 13.994 | 19.762 | 22.767 | 29.310 |
| Cash | - | - | - | - | - | - | 9.870 | 2.787 | 2.310 | 20.745 |
| Shareholders Funds | - | - | - | - | - | - | 14.372 | 16.398 | 17.294 | 32.854 |
| Social Capital | - | - | - | - | - | - | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | - | - | 9.528 | 9.095 | 9.160 | 18.570 |
| Income in Advance | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "2511 - 2511" | |||||||||
| CAEN Financial Year |
2511
|
|||||||||
Comments - Ubiphorma S.r.l.